<DOC>
	<DOCNO>NCT00002229</DOCNO>
	<brief_summary>The purpose study see safe effective give saquinavir ( soft gel capsule take mouth ) along 2 anti-HIV drug HIV-infected patient .</brief_summary>
	<brief_title>Safety Effectiveness Adding Saquinavir ( FORTOVASE ) Soft Gel Capsule Form Anti-HIV Drug Combination HIV-Infected Patients</brief_title>
	<detailed_description>Prior initiation study treatment patient screen baseline lab value take . Patients receive study treatment , FORTOVASE , two time day plus 2 new NRTI 's . Assessments perform specify interval throughout duration treatment .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are HIVpositive . Have HIV count 5,000 copies/ml . Have CD4 count 100 cells/mm3 . Meet specific requirement ever take NRTIs . Are 16 64 year old ( need consent 18 ) . Agree use effective method birth control study . Exclusion Criteria You eligible study : Have take nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) protease inhibitor ( PIs ) 2 week . Have take available NRTIs . Have certain serious medical condition , include severe liver disease active opportunistic ( AIDSrelated ) infection . Have history weight loss , muscle pain , loss appetite . Have take certain medication , include antiHIV drug require study . Are pregnant breastfeeding . Abuse alcohol drug . Are unable complete study reason .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 1999</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Dosage Forms</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>